Alzheimer’s and other dementia disproportionately affect older Black and Hispanic Americans compared to older Whites. In fact, Black Americans are twice as likely to develop Alzheimer’s, and Hispanic Americans are one and a half times more likely to develop the disease. Yet much of the Alzheimer’s research to date has not included sufficient numbers of Black, Hispanic, Asian or Native Americans to be representative of the U.S. population. The underrepresentation of these populations not only hinders the ability of researchers to understand these health disparities, it also restricts their knowledge of how an approved therapy or diagnostic may affect the populations most likely to need the treatment.
The bipartisan Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act, would increase the participation of underrepresented populations in Alzheimer’s and other dementia clinical trials by expanding education and outreach to these populations, encouraging the diversity of clinical trial staff and reducing participation burden, among other priorities. Introduced by Sens. Ben Ray Luján (D-N.M.) and Susan Collins (R-Maine), and Reps. Lisa Blunt Rochester (D-Del.), Jaime Herrera Beutler (R-Wash.) Chris Smith (R-N.J.), John Curtis (R-Utah) and Maxine Waters (D-Calif.) AIM is proud to support this critical, bipartisan legislation. Help us grow bipartisan support for the ENACT Act in Congress.
Letters-to-the-Editor (LTE) are a great way to grow support for our public policy priorities. Click below for talking points that can be used to help you write a LTE urging your member to cosponsor the ENACT act.
With help from volunteers like you we’re making sure policymakers hear directly from people impacted by Alzheimer’s. But our work isn’t done. Join us.
Everything you need to make the most of your year around advocacy efforts are available in this Advocate’s Guide. We’ll be updating this guide throughout the year as our policy priorities are introduced in Congress.